ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.6449_6450del (p.Lys2150fs) (rs80359594)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Breast Cancer Information Core (BIC) (BRCA2) RCV000113591 SCV000146858 pathogenic Breast-ovarian cancer, familial 2 2005-09-27 no assertion criteria provided clinical testing
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge RCV000113591 SCV000327433 pathogenic Breast-ovarian cancer, familial 2 2015-10-02 criteria provided, single submitter clinical testing
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000113591 SCV000301050 pathogenic Breast-ovarian cancer, familial 2 2016-09-08 reviewed by expert panel curation Variant allele predicted to encode a truncated non-functional protein.
GeneDx RCV000484644 SCV000564790 pathogenic not provided 2015-02-16 criteria provided, single submitter clinical testing This deletion of 2 nucleotides in BRCA2 is denoted c.6449_6450delAA at the cDNA level and p.Lys2150SerfsX25 (K2150SfsX25) at the protein level. The normal sequence, with the bases that are deleted in brackets, is ATTA[AA]GTTT. The deletion causes a frameshift, which changes a Lysine to a Serine at codon 2150, and creates a premature stop codon at position 25 of the new reading frame. This variant is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. BRCA2 c.6449_6450delAA, previously reported as 6677_6678delAA, has been observed in association with breast and/or ovarian cancer (Foretova 2004). we consider this variant to be pathogenic.
Integrated Genetics/Laboratory Corporation of America RCV000590435 SCV000694973 pathogenic Hereditary breast and ovarian cancer syndrome 2017-02-03 criteria provided, single submitter clinical testing Variant summary: The BRCA2 c.6449_6450delAA (p.Lys2150Serfs) variant results in a premature termination codon, predicted to cause a truncated or absent BRCA2 protein due to nonsense mediated decay, which are commonly known mechanisms for disease. One in silico tool predicts a damaging outcome for this variant. This variant is absent in 118150 control chromosomes. Multiple publications cite this variant in affected individuals. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.